Literature DB >> 34674000

Analysis of incidence and risk factors of the multidrug resistant gastrointestinal tract infection in children and adolescents undergoing allogeneic and autologous hematopoietic cell transplantation: a nationwide study.

Małgorzata Salamonowicz-Bodzioch1, Jowita Frączkiewicz2, Krzysztof Czyżewski3, Olga Zając-Spychała4, Ewa Gorczyńska2, Grażyna Wróbel2, Bernarda Kazanowska2, Dorota Sęga-Pondel2, Jadwiga Węcławek-Tompol2, Marek Ussowicz2, Krzysztof Kałwak2, Mariusz Wysocki3, Magdalena Dziedzic3, Jacek Wachowiak4, Agnieszka Zaucha-Prażmo5, Jerzy Kowalczyk5, Jolanta Goździk6, Jan Styczyński3.   

Abstract

The aim of this multi-center study was to evaluate the incidence, clinical course, and risk factors for bacterial multidrug-resistant (MDR) gastrointestinal tract infections (GTI) among children undergoing allogeneic and autologous hematopoietic cell transplantation. A total number of 175 pediatric patients (aged 1-18 years), transplanted between January 2018 and December 2019, who were tested for bacterial colonization/infection were enrolled into this multi-center analysis. Episodes of MDR GTI occurred in 77/175 (44%) patients. In multivariate analysis for higher GTI incidence, the following factors were significant: matched-unrelated donor (MUD) transplantation, HLA mismatch, presence of graft-versus-host disease (GVHD), and gut GVHD. The most common GTI were Clostridium difficile (CDI), multidrug-resistant Enterobacteriaceae (Klebsiella pneumoniae, Escherichia coli extended-spectrum β-lactamase), and Enterococcus HLAR (high-level aminoglycoside-resistant). No MDR GTI-attributed deaths were reported. MDR GTI is a frequent complication after HCT among children, causes prolonged hospitalization, but rarely contributes to death. We identified risk factors of MDR GTI development in children, with focus on GVHD and unrelated donor and HLA mismatch. We conclude that the presence of Clostridiales plays an important anti-inflammatory homeostatic role and decreases incidence of GVHD or alleviate its course.
© 2021. The Author(s).

Entities:  

Keywords:  Autologous transplantation; Clostridium difficile; Gastrointestinal tract infection; Gram-negative multidrug-resistant bacteria; Hematopoietic stem cell transplantation; Malignant diseases; Pediatric hematology and oncology

Mesh:

Year:  2021        PMID: 34674000      PMCID: PMC8720737          DOI: 10.1007/s00277-021-04681-y

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  38 in total

1.  Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients.

Authors:  A L Oliveira; M de Souza; V M H Carvalho-Dias; M A Ruiz; L Silla; P Yurie Tanaka; B P Simões; P Trabasso; A Seber; C J Lotfi; M A Zanichelli; V R Araujo; C Godoy; A Maiolino; P Urakawa; C A Cunha; C A de Souza; R Pasquini; M Nucci
Journal:  Bone Marrow Transplant       Date:  2007-04-16       Impact factor: 5.483

2.  Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome.

Authors:  Ami S Bhatt; Samuel S Freeman; Alex F Herrera; Chandra Sekhar Pedamallu; Dirk Gevers; Fujiko Duke; Joonil Jung; Monia Michaud; Bruce J Walker; Sarah Young; Ashlee M Earl; Aleksander D Kostic; Akinyemi I Ojesina; Robert Hasserjian; Karen K Ballen; Yi-Bin Chen; Gabriela Hobbs; Joseph H Antin; Robert J Soiffer; Lindsey R Baden; Wendy S Garrett; Jason L Hornick; Francisco M Marty; Matthew Meyerson
Journal:  N Engl J Med       Date:  2013-08-08       Impact factor: 91.245

3.  Antibiotic-Induced Depletion of Anti-inflammatory Clostridia Is Associated with the Development of Graft-versus-Host Disease in Pediatric Stem Cell Transplantation Patients.

Authors:  Tiffany R Simms-Waldrip; Gauri Sunkersett; Laura A Coughlin; Milan R Savani; Carlos Arana; Jiwoong Kim; Minsoo Kim; Xiaowei Zhan; David E Greenberg; Yang Xie; Stella M Davies; Andrew Y Koh
Journal:  Biol Blood Marrow Transplant       Date:  2017-02-09       Impact factor: 5.742

4.  Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome.

Authors:  Lise Willems; Raphaël Porcher; Matthieu Lafaurie; Isabelle Casin; Marie Robin; Aliénor Xhaard; Anna Lisa Andreoli; Paula Rodriguez-Otero; Nathalie Dhedin; Gérard Socié; Patricia Ribaud; Régis Peffault de Latour
Journal:  Biol Blood Marrow Transplant       Date:  2012-02-28       Impact factor: 5.742

5.  Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Authors:  Francesca Patriarca; Chiara Cigana; Dozzo Massimo; Davide Lazzarotto; Antonella Geromin; Miriam Isola; Marta Lisa Battista; Marta Medeot; Michela Cerno; Alessandra Sperotto; Anna Candoni; Massimo Crapis; Assunta Sartor; Claudio Scarparo; Matteo Bassetti; Renato Fanin
Journal:  Biol Blood Marrow Transplant       Date:  2016-11-04       Impact factor: 5.742

6.  Abdominal complications after bone marrow transplantation in children: sonographic and CT findings.

Authors:  E C Benya; C J Sivit; R R Quinones
Journal:  AJR Am J Roentgenol       Date:  1993-11       Impact factor: 3.959

Review 7.  Prevention of infectious complications in pediatric HSCT.

Authors:  J Styczynski; L Gil
Journal:  Bone Marrow Transplant       Date:  2008-10       Impact factor: 5.483

Review 8.  Bacterial Infections in Hematopoietic Stem Cell Transplant Recipients.

Authors:  Elisa Balletto; Małgorzata Mikulska
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-07-01       Impact factor: 2.576

Review 9.  Clostridium difficile Infection in Special High-Risk Populations.

Authors:  Alberto Cózar-Llistó; Antonio Ramos-Martinez; Javier Cobo
Journal:  Infect Dis Ther       Date:  2016-08-11

10.  Characterization of the 17 strains of regulatory T cell-inducing human-derived Clostridia.

Authors:  Seiko Narushima; Yuki Sugiura; Kenshiro Oshima; Koji Atarashi; Masahira Hattori; Makoto Suematsu; Kenya Honda
Journal:  Gut Microbes       Date:  2014-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.